Table 4  Ovarian toxicity of different chemotherapeutic drugs (modified from 4 ,  5 ).

Risk	Regimen/Substance
High risk (> 80% risk of permanent amenorrhea)	CMF, CEF, CAF, TAC × 6 for women aged ≥ 40 years Conditioning for stem cell transplantation (particularly alkylating agent-based myeloablative conditioning with busulfan, cyclophosphamide, melphalan) BEACOPP × 6 – 8 for women aged > 35 years
Intermediate risk (40 – 60% risk of permanent amenorrhea)	CMF, CEF, CAF, TAC × 6 for women aged 30 – 39 years AC × 4 for women aged ≥ 40 years AC or EC × 4 → taxane BEACOPP × 6 – 8 for women aged 25 – 35 years CHOP × 6 for women aged ≥ 35 years Standard therapies for bone and soft tissue sarcomas
Low risk (< 20% risk of permanent amenorrhea)	CMF, CEF, CAF, TAC × 6 for women aged ≤ 30 years AC × 4 for women aged ≤ 40 years BEACOPP × 6 – 8 for women aged < 25 years ABVD × 2 – 4 CHOP × 6 for women aged < 35 years CVP AML-type therapy (anthracyclines/ cytarabine) ALL-type therapy (multi-agent) FOLFOX for women aged ≤ 40 years
Very low or no risk of permanent amenorrhea	Methotrexate Fluorouracil Vincristine